UY30682A1 - Nueva difenilazetidinona sustituida con acido piperazina-1-sulfonico con propiedades farmacologicas mejoradas - Google Patents

Nueva difenilazetidinona sustituida con acido piperazina-1-sulfonico con propiedades farmacologicas mejoradas

Info

Publication number
UY30682A1
UY30682A1 UY30682A UY30682A UY30682A1 UY 30682 A1 UY30682 A1 UY 30682A1 UY 30682 A UY30682 A UY 30682A UY 30682 A UY30682 A UY 30682A UY 30682 A1 UY30682 A1 UY 30682A1
Authority
UY
Uruguay
Prior art keywords
new
pharmacological properties
difenilazetidinona
piperazina
replaced
Prior art date
Application number
UY30682A
Other languages
English (en)
Inventor
Dr Werner Kramer
Dr Gerhard Jaehne
Dr Hubert Heuer
Dr Hans-Ludwig Schaefer
Dr Andreas Lindenschmidt
Wendelin Frick
Claus-Dieter Graf
Wolfgang Schmider
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of UY30682A1 publication Critical patent/UY30682A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Nueva difenilazetidinona sustituida con ácido piperazina-1-sulfonico y que tiene propiedades farmacologicas mejoradas.La invencion se refiere al compuesto de la formula I y sus sales fisiologicamente toleradas. El compuesto es adecuado, por ejemplo, como hipolipidémico
UY30682A 2006-11-02 2007-10-31 Nueva difenilazetidinona sustituida con acido piperazina-1-sulfonico con propiedades farmacologicas mejoradas UY30682A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006051655 2006-11-02

Publications (1)

Publication Number Publication Date
UY30682A1 true UY30682A1 (es) 2008-07-03

Family

ID=38875004

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30682A UY30682A1 (es) 2006-11-02 2007-10-31 Nueva difenilazetidinona sustituida con acido piperazina-1-sulfonico con propiedades farmacologicas mejoradas

Country Status (20)

Country Link
US (1) US20090264402A1 (es)
EP (1) EP2091915A1 (es)
JP (1) JP2010508313A (es)
KR (1) KR20090091120A (es)
CN (1) CN101535249A (es)
AR (1) AR063747A1 (es)
AU (1) AU2007315327A1 (es)
BR (1) BRPI0718052A2 (es)
CA (1) CA2668094A1 (es)
CL (1) CL2007003175A1 (es)
CO (1) CO6160306A2 (es)
IL (1) IL198427A0 (es)
MA (1) MA30819B1 (es)
MX (1) MX2009003823A (es)
NO (1) NO20091746L (es)
RU (1) RU2009120679A (es)
TW (1) TW200826941A (es)
UY (1) UY30682A1 (es)
WO (1) WO2008052658A1 (es)
ZA (1) ZA200901981B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2200609A1 (en) 2007-09-10 2010-06-30 Prosidion Limited Compounds for the treatment of metabolic disorders
EP2403848A1 (en) 2009-03-06 2012-01-11 Lipideon Biotechnology AG Pharmaceutical hypocholesterolemic compositions
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
KR101898610B1 (ko) 2010-08-31 2018-09-14 서울대학교산학협력단 ＰＰＡＲδ 활성물질의 태자 재프로그래밍 용도
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
RU2737434C2 (ru) 2013-03-13 2020-11-30 Форма Терапьютикс, Инк. Новые соединения и композиции для ингибирования fasn
CN104193731B (zh) * 2014-08-27 2017-03-15 广东东阳光药业有限公司 一种脲取代联苯类化合物及其组合物及用途
CN104513187B (zh) * 2015-01-09 2017-05-31 安润医药科技（苏州）有限公司 依折麦布及其中间体的合成方法
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10227506A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders

Also Published As

Publication number Publication date
EP2091915A1 (de) 2009-08-26
ZA200901981B (en) 2010-03-31
MX2009003823A (es) 2009-05-11
CA2668094A1 (en) 2008-05-08
US20090264402A1 (en) 2009-10-22
RU2009120679A (ru) 2010-12-10
AR063747A1 (es) 2009-02-18
TW200826941A (en) 2008-07-01
CL2007003175A1 (es) 2008-05-16
NO20091746L (no) 2009-07-21
WO2008052658A1 (de) 2008-05-08
CO6160306A2 (es) 2010-05-20
KR20090091120A (ko) 2009-08-26
AU2007315327A1 (en) 2008-05-08
JP2010508313A (ja) 2010-03-18
IL198427A0 (en) 2010-02-17
CN101535249A (zh) 2009-09-16
MA30819B1 (fr) 2009-10-01
BRPI0718052A2 (pt) 2015-06-16

Similar Documents

Publication Publication Date Title
UY30682A1 (es) Nueva difenilazetidinona sustituida con acido piperazina-1-sulfonico con propiedades farmacologicas mejoradas
CO6640320A2 (es) Composición de control de fitoenfermedades y metodo de control de fitoenfermedades
ECSP11011348A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3
ATE517869T1 (de) Herstellung substituierter morphinan-6-one und salzen und zwischenprodukten davon
BRPI1012638B8 (pt) métodos e intermediários para preparar agentes farmacêuticos
MX2009013276A (es) Compuestos anti-inflamatorios de ciclobutenodiona sustituida.
PE20141174A1 (es) Compuestos de pirrol como inhibidores de la bomba de protones
BRPI0821102A2 (pt) Preparação de derivados de di-hidropirrol como intermediários
AR076603A1 (es) Procedimiento para la fabricacion de productos intermedios de dronedarona
CR10557A (es) Bencilaminas, un proceso para la produccion y su uso como agentes antiinflamatorios
BRPI0919826A2 (pt) Micro-organismo para a producao de acido succinico.
SV2004001756A (es) Nueva difenilazetidinona con propiedades fisiologicas mejoraradas, procedimiento para su preparacion, medicamentos que comprenden este compuesto y su uso
CO6410291A2 (es) 3-amino-2-mercaptoquinolina sustituidacomo modulador de kcnq2/3
CR11463A (es) Compuestos de piridilmetil-sulfonamida
ECSP11011345A (es) 2-mercapto-3-aminopiridina sustituida como moduladores de kcnq2/3
BR112012017845A2 (pt) novo processo para produção de derivados de benzofenona
TN2010000072A1 (en) New compounds
UY31469A1 (es) Nuevos hidratos de difenilazetidinona cristalinos, medicamentos que comprenden a estos compuestos y uso de los mismos
CR11506A (es) Uso de derivados de acido tetramico para controlar nematodos
AR060189A1 (es) Sales de malato y polimorfos de acido (3s, 5s)-7-[3-amino-5-metil-piperidinil]-1-ciclopropil-1,4-dihidro-8-metoxi-4-oxo-3-quinolincarboxilico
BR112012008017A2 (pt) 1,2,4-triazina, utilização de uma 1,2,4-triazina e processo de preparação de uma 1,2,4-triazina
BR112015007821A2 (pt) processo para a preparação de voriconazol e análogos do mesmo
BR112013011244A2 (pt) processo para a preparação de derivados e ácido 3-(6-amino-piridin-3il)-2-acrílico
BR112014010037A8 (pt) processo para a produção e estabilização de composi-ções de policarbonato modificadas por impacto usando soluções diluídas de compostos ácidos
BR112012015708A2 (pt) novo processo para produção de 4-aminobut-2-enolidas a partir de 4-alcoxifuran-2 (5h) -ona ou 4-arilalcoxfuran-2 (5h) -ona

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20120606